The purpose of this study is to test if low dose radiation, which is routinely used in treating patients with lung cancer for symptom control, can improve the results from the standard treatment with pembrolizumab and chemotherapy. In this study, only individuals who have NSCLC that is advanced (Stage IV), or has come back (recurred), will be able to participate.
1 Primary · 4 Secondary · Reporting Duration: Up to Week 70 (1 Year following Completion of Treatment Cycle 6)
40 Total Participants · 1 Treatment Group
Primary Treatment: Untreated Patients With Stage IV NSCLC · No Placebo Group · Phase 2
Age 18 - 100 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: